Related Experiment Videos
[Clinico-pharmacologic studies on pefloxacin]
1Fövárosi Onkormányzat Péterfy Sándor u. Kórház, A Belgyógyászati Osztály és Klinikai Farmakológia, Budapest.
Orvosi Hetilap
|March 27, 1994
Summary
Pefloxacin elimination slows in elderly patients and those with liver or kidney impairment, leading to increased drug accumulation. Dose reduction may be considered, but caution is advised for severe infections due to variable patient responses.
Area of Science:
- Pharmacology
- Clinical Pharmacy
- Drug Metabolism
Background:
- Pefloxacin pharmacokinetics can be influenced by physiological changes.
- Age-related decline, liver impairment, and renal insufficiency are common in patient populations.
- Understanding these impacts is crucial for safe and effective pefloxacin dosing.
Purpose of the Study:
- To investigate the pharmacokinetic profile of pefloxacin in patients with liver impairment, renal insufficiency, and advanced age.
- To assess the impact of these conditions on pefloxacin elimination and accumulation.
- To provide guidance on appropriate pefloxacin dosing strategies.
Main Methods:
- A pharmacokinetic study involving 55 patients with various infections.
- Patients received oral or intravenous pefloxacin (400 mg twice daily).
- Blood samples were collected on days 1 and 7 of therapy for analysis.
Main Results:
- Pefloxacin pharmacokinetics exhibited significant interindividual variability, increasing with multiple dosing.
- Elimination rate decreased during therapy, suggesting reduced metabolism.
- Elderly patients and those with renal or hepatic impairment showed decreased pefloxacin elimination and greater accumulation.
Conclusions:
- Dose reduction of pefloxacin may be beneficial for elderly patients and those with renal or hepatic impairment.
- While lower doses can be effective for mild infections, caution is needed in severe infections due to unpredictable serum concentrations.
- Individualized dosing adjustments are recommended based on patient-specific factors.